The Korean Brain Research Institute (KBRI, President Suh Pann-gil) announced on the 21st that the research team led by Hyang-sook Huh, Ph.D., a senior researcher in the Degenerative Brain Disease Research Group, first discovered that the A drug ‘abemacicli mesylate’, used as a treatment for breast cancer, is also effective in treating Alzheimer’s disease.
The research team noted that Abemasilclip is a multi-target drug (reducing amyloid plaques, preventing tau lesions, preventing brain inflammation and improving memory) aimed at treating Alzheimer’s disease by controlling ‘CDK4/6’, a gene associated with cell cycle regulation. .
The research team confirmed that the formation of dendrites in neurons was promoted and short-term memory and recognition memory were restored in an Alzheimer’s disease animal model injected with this drug. In addition, they found that brain inflammation, amyloidopathy, and tauopathy were prevented by regulating the expression of specific genes (tau kinase DYRK1A and p-GSK3β) in an animal model of dementia where amyloid or tau associated with Alzheimer’s disease was over-expressed. to express
In addition, when abemaciclib regulates glial cell hyperactivity caused by amyloid beta or ‘LPS (an artificial inflammatory drug in model animals)’, it inhibits the ‘DYRK1A/STAT3’ signaling system, causing inflammation the brain. to suppress Cain’s expression.
Although previous studies have shown that the expression of the ‘CDK4’ gene is increased in the brains of Alzheimer’s disease patients compared to normal people, and that the control of ‘CDK4/6’ genes regulates peripheral inflammation, studies on the correlation between a drug called abemaciclib and Alzheimer’s disease was not maintained. This is the first time. In the future, he plans to focus on research on the commercialization and industrialization of abemaciclib.
Dr. Heo Hyang-sook said, “This study confirms the possibility that the anticancer drug abemaciclib can also be used as a treatment for Alzheimer’s disease, which is a representative degenerative brain disease.
This study, in which researcher Lee Hyun-joo participated as the first author, was recently published in the online edition of ‘Pharmacological Research’, an international academic journal.
Daegu = Reporter Jeong Jae-hoon jhoon@etnews.com
